One year later, Amazon GDPR fine details remain clouded
By 
Neil Hodge2022-07-29T14:25:00
It’s been one year since online retailer Amazon announced it was on the receiving end of a record €746 million (U.S. $758 million) fine under the General Data Protection Regulation, but details about the decision—as well as the actual complaint—remain sketchy.
Related articles
-
News BriefAmazon unit fined $35M under GDPR for employee productivity tracking
Amazon’s warehouse management arm in France was assessed a penalty of €32 million (U.S. $35 million) for violating the General Data Protection Regulation by excessively tracking the productivity of employees.
-
News BriefFTC sues Amazon over Prime enrollment, ‘cancellation trickery’
The Federal Trade Commission filed a complaint against e-commerce giant Amazon for allegedly enrolling consumers into Amazon Prime without their consent and making it difficult to cancel Prime subscriptions.
-
ArticleAmazon transport arm GDPR fine imparts lesson on criminal record checks
Amazon Road Transport was fined €2 million (U.S. $2.2 million) for trying to carry out criminal record checks on freelance truck drivers it wanted to hire without Spanish law to back up the practice.
More from Regulatory Enforcement
-
News BriefFinCEN flags $9 billion in Iranian shadow-banking activity, citing SARs filings from U.S. banks
Approximately $9 billion of potential shadow-banking flows tied to Iranian networks in 2024, according to a new analysis from FinCEN. The report highlights how illicit funds are making their way through financial institutions as they meet the requirements of the Bank Secrecy Act (BSA).
-
News BriefCFPB ends probe into Meta’s financial advertising practices
Meta says it is no longer under investigation by the U.S. Consumer Financial Protection Bureau (CFPB), the latest instance of the agency scaling back enforcement under President Donald Trump.
-
News BriefTexas sues Johnson & Johnson, Kenvue over alleged misleading marketing of Tylenol
Texas Attorney General Ken Paxton sued two pharmaceutical companies for ”deceptively marketing Tylenol to pregnant mothers” despite risks linked to autism. The filing came two days before HHS Secretary Robert F. Kennedy Jr. appeared to walk back the claims.